Rubicon Research Limited has submitted its Q3 FY26 earnings conference call transcript to stock exchanges, revealing strong financial performance and management's optimistic outlook for future growth.

Strong Q3 FY26 Financial Performance

The company delivered robust financial results for the quarter ended December 31, 2025, with significant year-over-year improvements across key metrics.

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the company maintained strong momentum with revenue reaching ₹1,240 crores, up 34% year-over-year.

R&D Investment and Future Growth Strategy

CEO Parag Sancheti emphasized the company's strong R&D-driven growth model during the February 3, 2026 earnings call. The company maintained R&D expenses at ₹52 crores for the quarter, representing 11% of revenue, in line with guidance of 10%-11%.

Sagar Oak, Senior Vice President of Corporate Development and Strategy, presented compelling data showing improving R&D productivity. The analysis revealed that R&D investment returns have increased from 3.3x to 5.7x over rolling three-year periods, demonstrating enhanced efficiency in product development and commercialization.

Pithampur Facility Expansion

The company is progressing with operationalizing its newly acquired Pithampur manufacturing facility, expected to be validated by mid-2026 with commercialization beginning in Q1 CY'27. This facility will provide capabilities for high potent oncology, hormones, and steroids production.

Specialty Products Growth

The specialty portfolio continues to strengthen, contributing 31%-32% of gross profit in Q2 and Q3, higher than the 26.9% contribution in full year FY25. Management highlighted successful launches including Fluticasone, where the company became the third to receive approval since 2007.

Management Guidance and Outlook

CFO Nitin Jajodia reaffirmed the company's commitment to maintaining operating EBITDA margins in the 22%-23% range despite temporary gross margin pressure from increased outsourcing to meet higher-than-expected demand. The company expects to invest over ₹500 crores in R&D across fiscals 2026, 2027, and Q1 2028, supporting continued revenue growth visibility through FY30.

The earnings call transcript was submitted to BSE and NSE on February 6, 2026, by Company Secretary Deepakshree Tanksale, maintaining regulatory compliance under SEBI listing requirements.

Rubicon Research Limited's Board of Directors conducted a comprehensive meeting on February 3, 2026, addressing multiple strategic and governance matters in compliance with SEBI Listing Regulations. The company formally disclosed these developments through regulatory filings to BSE (Scrip Code: 544578) and NSE (Scrip Symbol: RUBICON).

Board Composition Changes

The board approved significant changes to its composition, implementing both new appointments and noting departures. On the recommendation of the Nomination and Remuneration Committee, the board approved the appointment of Dr. Pradnya Saravade as Additional Independent Woman Director.

Dr. Saravade brings extensive governance and administrative experience as a former Indian Police Service officer. She holds MBBS and MS (General Surgery) degrees and has served in various leadership positions including heading the Maharashtra Railway Police, working with the Securities and Exchange Board of India (SEBI) for three years, and serving as Joint Managing Director of Maharashtra State Police Housing Corporation Limited. She has also worked with the Central Bureau of Investigation (CBI) for four years and has been awarded the Indian Police Medal for Distinguished Services.

Director Resignation

Simultaneously, the board noted the resignation of Mr. Anand Agarwal (DIN: 06481297) as Non-Executive Director, nominated by General Atlantic Singapore RR Pte Ltd. His resignation became effective from the close of business on February 3, 2026, due to other pressing commitments.

Secretarial Auditor Appointment

Following the Audit Committee's recommendation, the board approved the appointment of M/s. BNP & Associates, Practicing Company Secretaries, as the company's Secretarial Auditor.

BNP & Associates is a peer-reviewed firm established in October 2014, specializing in secretarial audit, corporate advisory services, and compliance management. The firm maintains four partners, one associate partner, and 15 executive team members, including eight qualified Company Secretaries.

Subsidiary Merger Approval

The board granted in-principle approval for the merger of KIA Health Tech Private Limited, a wholly-owned subsidiary, with Rubicon Research Limited. This strategic decision aims to achieve operational synergies between the entities.

KIA Health Tech was incorporated on July 19, 2021, to establish a pharmaceuticals manufacturing facility in Aurangabad. The merger will involve no cash consideration since KIA Health Tech is wholly-owned by Rubicon Research. Upon completion, all shares held by Rubicon Research in KIA Health Tech will be automatically cancelled without affecting the parent company's shareholding pattern.

Regulatory Compliance and Meeting Details

The Board meeting commenced at 3:00 PM (IST) and concluded at 4:30 PM (IST) on February 3, 2026. All decisions were made in accordance with SEBI Listing Regulations and the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2024/0155. The company filed detailed disclosures with BSE and NSE under Regulation 30 requirements. The merger plan remains subject to board approval of the scheme of arrangement, various regulatory approvals, and other administrative formalities.